If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...

5-Fluorouracil 4% cream achieved total clearance in 54.5% and partial clearance in 24.2% of hyperkeratotic actinic keratosis (AK) lesions at 3 months, demonstrating a good safety profile with high ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...